ClinVar Miner

Submissions for variant NM_032737.4(LMNB2):c.704G>A (p.Arg235Gln)

gnomAD frequency: 0.01005  dbSNP: rs121912497
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000551638 SCV000656065 benign Progressive myoclonic epilepsy type 9; Lipodystrophy, partial, acquired, susceptibility to 2024-01-29 criteria provided, single submitter clinical testing
Mendelics RCV000990135 SCV001140952 benign Progressive myoclonic epilepsy type 9 2019-05-28 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000057200 SCV001144437 benign not provided 2018-12-12 criteria provided, single submitter clinical testing
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV000015561 SCV001435271 likely benign Acquired partial lipodystrophy criteria provided, single submitter research The heterozygous p.Arg235Gln variant in LMNB2 has been identified in 2 individuals with acquired partial lipodystrophy (PMID: 16826530), but has also been identified in >1% of European (non-Finnish) chromosomes and 27 homozygotes by ExAC (http://gnomad.broadinstitute.org/). Acquired partial lipodistrophy is not known to be a Mendelian genetic disease. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely benign for acquired partial lipodystrophy.
CeGaT Center for Human Genetics Tuebingen RCV000057200 SCV002546036 benign not provided 2024-01-01 criteria provided, single submitter clinical testing LMNB2: BP4, BS1, BS2
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago RCV003224099 SCV003920152 likely benign Progressive myoclonic epilepsy type 9; Lipodystrophy, partial, acquired, susceptibility to; Microcephaly 27, primary, autosomal dominant 2022-05-26 criteria provided, single submitter clinical testing This variant has been reported in the literature in at least 2 individuals with acquired partial lipodystrophy as well as 1 individual with familial partial lipodystrophy (Hegele 2006 PMID:16826530, Akinci 2017 PMID:28641778). This variant is present in the Genome Aggregation Database (Highest reported MAF 1.5% (160/10626) including 3 homozygotes (https://gnomad.broadinstitute.org/variant/19-2435152-C-T?dataset=gnomad_r3). This variant is present in ClinVar, with several labs classifying this variant as Likely Benign or Benign (Variation ID:14474). Evolutionary conservation and computational predictive tools suggest that this variant may not impact the protein. In summary, data on this variant suggests that this variant does not cause disease but requires further evidence. Therefore, this variant is classified as likely benign.
OMIM RCV000015561 SCV000035826 risk factor Acquired partial lipodystrophy 2006-08-01 no assertion criteria provided literature only
Epithelial Biology; Institute of Medical Biology, Singapore RCV000057200 SCV000088313 not provided not provided no assertion provided not provided
Genetic Services Laboratory, University of Chicago RCV000117496 SCV000151714 likely benign not specified no assertion criteria provided clinical testing Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.